The hereditary cancer syndromes hereditary leiomyomatosis and renal cell cancer (HLRCC) and succinate dehydrogenaserelated hereditary paraganglioma and pheochromocytoma (SDH PGL/PCC) are linked to germline loss-of-function mutations in genes encoding the Krebs cycle enzymes fumarate hydratase and succinate dehydrogenase, thus leading to elevated levels of fumarate and succinate, respectively 1-3 . Here, we report that fumarate and succinate both suppress the homologous recombination (HR) DNA-repair pathway required for the resolution of DNA double-strand breaks (DSBs) and for the maintenance of genomic integrity, thus rendering tumor cells vulnerable to synthetic-lethal targeting with poly(ADP)-ribose polymerase (PARP) inhibitors. These results identify HLRCC and SDH PGL/PCC as familial DNA-repair deficiency syndromes, providing a mechanistic basis to explain their cancer predisposition and suggesting a potentially therapeutic approach for advanced HLRCC and SDH PGL/PCC, both of which are incurable when metastatic.
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NATuRe GeNeTiCS Supplementary Fig. 1m ). The elevated DSBs were suppressed in these lines after complementation by transient expression of wildtype FH through plasmid transfection ( Fig. 2e and Supplementary  Fig. 1n ), thus further supporting the link between fumarate and suppression of HR.
In addition to γ H2AX foci, increased phosphorylated 53BP1 (p53BP1) nuclear foci are also markers of the cellular response to DNA DSBs, and HR-deficient cells show elevated levels of γ H2AX and p53BP1 foci in the absence of exogenous DNA damage 6 . We found that shRNA knockdown of SDHB or FH resulted in high levels of γ H2AX and p53BP1 foci, and that these foci levels were similar in magnitude to those seen in the context of short interfering RNA (siRNA) knockdown of BRCA1, BRCA2 and RAD51, central factors in the HR pathway ( Fig. 2f-i ). High levels of these foci were also seen in UOK 262, UOK 268 and NCCFH1 cells (Fig. 2h,i) .
To directly test for DNA DSB-repair deficiency, we used two different luciferase-based DNA-repair assays 6,10-13 able to report either HR or nonhomologous end-joining (NHEJ) activity (Fig. 2j ). These assays can indicate the relative differences in pathway-specific DNA DSB-repair activity across cell lines ( Supplementary Fig. 1o ). We noted suppression of the HR pathway, along with a slight increase in the NHEJ pathway, as a function of both SDHB or FH knockdown (Fig. 2k,l and Supplementary Fig. 1p ) and in the patient-derived HLRCC cell lines (Fig. 2m ). Complementation by expression of wild-type FH rescued HR function (Fig. 2m ). Next, we sought to further evaluate the extent of the HR suppression by using U2OS cells and the well-established DR-GFP assay, a chromosomal reporter assay for HR that is widely used as a benchmark assay in the DNA-repair field 6, 14, 15 (Fig. 2n ). We found that siRNAs targeting SDHB or FH resulted in substantial suppression of HR and that this suppression was similar in magnitude to that seen with siRNAs targeting key HR proteins including BRCA1, BRCA2 and RAD51 ( Fig. 2o and Supplementary Fig. 2q ). Another measure of HR ability is the formation of RAD51 foci in response to DNA damage. ---3  2  3  --2  2  3  2  3  4  4  3  2  3  1  2  3  3  ---T stage   ---T3a  T2  T4  --T3a  T1a  T1a  T1a  T3a  T3a  T4  T3a  T3a  T2a  T2b  T2a  T3a  T3a --- . This analysis was independently performed n = 3 times with similar results, and images were cropped around the known molecular weight of the band of interest. Vinc, vinculin loading control. Full blots are shown in Supplementary Fig. 6 . b,c, LC-MS quantification of succinate (b) and fumarate (c) after SDHB and FH knockdown in YUNK1 cells and HLRCC cell lines. d, Quantification of neutral comet assay results in YUNK1 cells with or without SDHB or FH knockdown, compared with knockdown of the core HR factors BRCA1, BRCA2 and RAD51. e, Quantification of results of neutral comet assays performed in HLRCC patient-derived cell lines with (+ FH) or without FH plasmid complementation. f,g, Representative images (n = 3 repeat experiments) (f) and quantification (g) of γ H2AX-foci staining performed in HEK293FT cells with or without knockdown of the indicated factors. h,i, Quantification of γ H2AX (h) and p53BP1 (i) foci in YUNK1 shRNA models of SDHB and FH knockdown, in HLRCC cell lines (UOK 262, UOK 268 and NCCFH19), and after siRNA suppression of core HR factors in YUNK1 cells. j, Luciferase-based plasmid reactivation assay to report HR. k-m, Quantification of luciferase reactivation by HR in YUNK1 cells with shRNAs suppressing SDHB and FH (k), in doxycycline-inducible shRNAs targeting SDHB and FH in YUNK1 and HEK293FT cells (l), and in patient-derived HLRCC cell lines either transiently transfected (+ ) with an FH expression plasmid for complementation of the FH deficiency or mock transfected (-) (m). n, DR-GFP assay reporting HR in U2OS cells. o, Quantification of DR-GFP HR assay results after transfection of U2OS cells with siRNAs targeting SDHB or FH as well as core HR factors. iGFP, internal GFP repeat. p, Quantification of RAD51-foci formation after 2-Gy IR treatment of YUNK1 and HEK293FT cells with or without shRNA suppression of SDHB or FH. q, Representative images of RAD51-foci formation after 2-Gy IR in YUNK1 cells with or without shRNA suppression of SDHB or FH. This analysis was repeated n = 3 times; quantification in p. For b-e, g-i, k-m, o and p, statistical analyses were performed with two-sided t tests (df = 4); bars represent mean of 3 independent experiments ± s.e.m.

NATuRe GeNeTiCS
We observed that YUNK1 and HEK293FT cells with SDHB or FH knockdown had a deficiency in RAD51-foci formation after treatment with ionizing radiation (IR), in agreement with decreased HR (Fig. 2p,q and Supplementary Fig. 2r ).
We next tested whether elevated levels of fumarate and succinate in themselves might be sufficient to drive the HR deficiency associated with SDHB or FH loss. We found that addition of the metabolites and/or cell-permeable versions thereof (succinate, monoethyl 
Fig. 3 | High levels of succinate and fumarate suppress HR and induce elevated DNA DSBs in a pathway mediated by the lysine demethylases KDM4A
and KDM4B. a, Quantification of U2OS DR-GFP HR assay results after 24-h treatment with the indicated doses of the indicated metabolites. ME-, monoethyl; DM-dimethyl; DMSO, control. b, Quantification of luciferase reactivation by HR in YUNK1 cells after 24-h treatment with 2 mM succinate, 2 mM monoethyl succinate, 2 mM dimethyl succinate, 1 mM dimethyl fumarate or 60 µ M dimethyl fumarate. c,d, Quantification of neutral comet assays performed in YUNK1 cells after 24-h treatment with the indicated doses of dimethyl fumarate (c) and succinate (d). e, Representative images and corresponding quantification of HEK293FT cells treated with 2 mM succinate or 30 µ M dimethyl fumarate for 24 h before immunofluorescence staining for γ H2AX or DAPI staining for DNA. This analysis was independently performed n = 3 times with similar results, and quantification is shown in f. f,g, Quantification of γ H2AX (f) and p53BP1 (g) foci in HEK293FT cells treated with the indicated doses of metabolites. Pos, positive. h, Quantification of the results of neutral comet assays performed in UOK 262 and UOK 268 HLRCC cell lines with or without transient transfection with an FH expression construct (mock) or after 24 h treatment with the indicated doses of succinate or dimethyl fumarate or with DMSO control. NS, not significant. i, Western blot analysis of H3K36me3 and H3K9me3 levels in normal kidney and in patient-derived samples of PGL/PCC and HLRCC tumors, with numbering of samples corresponding to Fig. 1 . β -actin was used as a loading control, and YUNK shSDHB1 was included as a control. This analysis was independently performed n = 2 times with similar results, and images were cropped around the known molecular weight of the band of interest. Full blots appear in Supplementary Fig. 6 . j, Quantification and representative images of neutral comet assays performed in the HLRCC cell lines UOK 262 and UOK 268, with mock transfection, transfection with expression constructs for FH, KDM4A, KDM4B or KDM4C, or treatment with 2 mM dimethyl-α -KG (α KG). k, Quantification of the results of neutral comet assays performed in YUNK1 cells treated for 24 h with the indicated doses of metabolites, with concurrent mock transfection or transfection with KDM4A expression constructs or with 2 mM dimethyl-α -KG treatment. l, DR-GFP assay after treatment with the indicated doses of dimethyl succinate, dimethyl fumarate and/or dimethyl-α -KG. For a-d, f-h and j-l, statistical analyses were performed with two-sided t tests (df = 4); bars represent mean ± s.e.m. of n = 3 independent experiments.
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NATuRe GeNeTiCS succinate, dimethyl succinate, monoethyl fumarate and dimethyl fumarate) to the cell culture medium was sufficient to suppress HR in a dose-dependent manner, as measured with DR-GFP assays (Fig. 3a ). The metabolites alone were sufficient to suppress HR in YUNK1 cells, as measured with luciferase-based HR reporter assays ( Fig. 3b ). Metabolite treatment of the YUNK1 cells also induced elevated DNA DSBs in comet assays (Fig. 3c,d and Supplementary  Fig. 2a -c). Similar effects of the metabolites were seen in other cell lines ( Supplementary Fig. 2d -h). Increases in γ H2AX and p53BP1 foci were also produced by addition of succinate or dimethyl fumarate to the cell culture medium in the HEK293FT cells ( Fig. 3e -g) and YUNK1 cells ( Supplementary Fig. 2i-l) . In a demonstration of epistasis, exogenous fumarate and succinate had no further effect on the levels of DNA DSBs in the FH-deficient HLRCC cells UOK 262 and UOK 268, which already overproduced fumarate because of functional FH loss ( Fig. 3h ).
Mechanistically, fumarate and succinate have similar structures and are known to converge in function by competitively inhibiting α KG-dependent dioxygenases, including the lysine demethylases KDM4A and KDM4B, which we and others have shown to be key regulators of DNA repair 6, 16, 17 . To directly test for the predicted suppression of KDM4A and KDM4B activity, we performed western blots to measure the levels of Lys36-trimethylated histone H3 (H3K36me3) and Lys9-trimethylated histone H3 (H3K9me3), which are known targets for demethylation by KDM4A and KDM4B. We found that H3K36me3 and H3K9me3 levels were elevated in human tumors with SDHB or FH deficiency ( Fig. 3i ), in patient-derived HLRCC cell lines (UOK 262 and UOK 268) ( Supplementary Fig. 3a ), in YUNK1 and HEK293FT cells with SDHB or FH knockdown ( Supplementary Fig. 3a -c), and in xenograft tumors formed by HEK293FT cells with SDHB knockdown ( Supplementary Fig. 3d ), as compared with their respective controls. We also observed a dose-dependent increase in H3K36me3 and H3K9me3 levels after treatment of YUNK1 cells with increasing doses of fumarate and succinate ( Supplementary Fig. 3e ,f). These findings are suggestive of KDM4A and KDM4B inhibition by elevated levels of succinate and fumarate.
Next, we sought to test the hypothesis that the HR suppression conferred by fumarate and succinate might be mediated through this inhibition of KDM4A and KDM4B. Through forced expression of KDM4A or KDM4B, we rescued the elevated DSB phenotype (as measured with comet assays) of the two patient-derived HLRCC cell lines UOK 262 and UOK 268, as well as the comet phenotype in YUNK1 induced by exogenous fumarate and succinate ( Fig. 3j,k) . There was no effect seen when KDM4C was overexpressed, even though KDM4C is a member of the same JMJD2 family as KDM4A and KDM4B and shares substantial homology with them 18 , thus highlighting the specificity for the KDM4A and KDM4B proteins ( Fig. 3j ). Furthermore, the addition of α KG to the cells (to compete out the fumarate) also rescued the phenotype in the FH-deficient cells ( Fig. 3j ) as well as the HR defect induced by succinate or fumarate, as measured in DR-GFP assays (Fig. 3l ).
We next hypothesized that the HR defect conferred by SDH or FH deficiency might render cells sensitive to DNA-damaging agents. To test this possibility, we performed clonogenic survival assays, which showed that after SDHB or FH knockdown, as compared with control shRNA knockdown, cells had substantially decreased survival in response to IR, mitomycin C, cisplatin and etoposide ( Supplementary Fig. 4a-d) .
Clinically, an emerging strategy in the treatment of HR-deficient cancers is the use of PARP inhibitor (PARPi) drugs, which have recently been approved by the US Food and Drug Administration for use in patients with BRCA1/2-deficient cancers 19, 20 . We therefore tested the effects of fumarate and succinate on PARPi sensitivity. We observed that knockdown of SDHB and FH as well as addition of exogenous dimethyl fumarate or succinate to the culture medium induced dramatic sensitivity to the PARPi drugs olaparib and BMN-673 ( Fig. 4a,b and Supplementary Figs. 1e-i). The FH-deficient HLRCC cell line UOK 262 was markedly more sensitive to the PARPi BMN-673 ( Fig. 4c ) (and to mitomycin C; Supplementary  Fig. 4j ) than other cell lines of renal origin that are FH proficient. Exogenously added succinate and fumarate analogs also strongly sensitized HeLa cells to PARPi drugs ( Supplementary Fig. 4k,l) .
To test for this succinate-and fumarate-induced PARPi sensitivity in tumors in vivo, we assayed the effect of the PARPi BMN-673 on the growth of tumor xenografts formed in immunodeficient mice by HEK293FT cells expressing a nontargeting control shRNA (shCtrl), an shRNA to SDHB (shSDHB) or an shRNA to FH (shFH) (knockdown shown in Supplementary Fig. 1g ,h). (HEK293FT is a tumorigenic cell line transformed by expression of the SV40 large T antigen). We observed that BMN-673 significantly inhibited the growth of both the SDHB-deficient and FH-deficient tumors in two separate sets of in vivo efficacy studies. In one set, mice were treated starting 4 d after tumor cell implantation and showed robust suppression of tumor growth by the PARPi compared with the vehicle control alone in the shSDHB and shFH tumors, but showed no effect in the shCtrl tumors ( Fig. 4d-f ). In the second set, the mice were treated after the tumors had grown to a palpable size (95-150 mm 3 ) ( Fig. 4g -i). Again, BMN-673 inhibited the growth of the SDH-deficient and FH-deficient tumors (Fig. 4g,h) , 
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but there was no growth inhibition relative to vehicle control in xenografts formed from the HEK293FT cells expressing the control shCtrl (Fig. 4i ). LC-MS quantification of intratumoral BMN-673 levels 24 h after treatment showed no significant difference in drug levels between shSDHB and shCtrl HEK293FT tumors (Fig. 4j ). Furthermore, levels of poly(ADP)-ribose modification of cellular proteins, as measured by ELISA ( Fig. 4k ) and western blotting ( Supplementary Fig. 1a,b) , decreased to the same extent in the SDHB-knockdown tumors and the shCtrl tumors 24 h after BMN-673 treatment.
Next, we conducted a third in vivo efficacy study using tumors formed from the UOK 262 cells, which, as discussed above, are an HLRCC patient-derived cell line deficient in FH. We observed a significant growth delay with PARPi treatment administered daily to the mice beginning 4 d after implantation and continued on a longterm basis for 180 d (Fig. 4l) . In a fourth in vivo experiment, we treated mice with BMN-673 or with vehicle control starting when the UOK 262 xenografts had reached an average size of 250 mm 3 (after approximately 150 d of pretreatment growth). Again, we found that the PARPi treatment (but not vehicle control) resulted Letters NATuRe GeNeTiCS in a substantial growth delay in the FH-deficient tumors (Fig. 4m) . Together, these four in vivo tumor efficacy studies consistently indicated that PARPi treatment suppresses the growth of SDH-or FH-deficient tumors in mice.
The results presented here demonstrate that the metabolites overproduced in the hereditary cancer syndromes HLRCC and SDH PGL/PCC compromise HR DNA repair (Fig. 4n ). This finding identifies decreased DNA repair as a key oncogenic mechanism in these diseases; this mechanism is similar to those underlying the familial breast and ovarian cancer predisposition syndromes linked to the BRCA1 and BRCA2 genes. In addition, our finding that succinate and fumarate render tumor cells highly susceptible to synthetic-lethal targeting with PARPi drugs suggests a therapeutic strategy that may potentially be translated into the clinic for these otherwise difficult-to-treat malignancies.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0170-4.
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Methods Western blot analyses. Western blot analysis of protein levels was conducted by loading 30 μ g of whole cell lysate onto 4-20% polyacrylamide gels. Total protein was transferred to a nitrocellulose membrane. After being blocked with 5% milk, membranes were incubated with primary antibodies. The antibodies used were as follows: rabbit monoclonal anti-fumarase (D9C5, Cell Signaling Technologies), 1:1,000 in 5% BSA; mouse monoclonal anti-SDHB (21A11AE7, Abcam), 1:1,000 in 5% milk; mouse monoclonal anti-vinculin (SPM227, Abcam), 1:1,000 in 5% milk; rabbit polyclonal anti-histone 3, Lys36 trimethyl (9050, Abcam), 1:500 in 5% BSA; anti-histone 3, Lys9 trimethyl (D4W1U, Cell Signaling Technologies), 1:1,000 in 5% BSA; mouse monoclonal anti-β -actin (60008, Protein Tech), 1:5,000 in 5% milk; rabbit polyclonal anti-histone H3 (ab1791, Abcam), 1:5,000 in 5% BSA; rabbit polyclonal anti-poly(ADP)-ribose (4336-BPC-100, Trevigen), 1:5,000 in 5% BSA; mouse monoclonal anti-GAPDH (60004, Protein Tech), 1:5,000 in 5% milk; mouse monoclonal anti-BRCA2 (ab1, Millipore), 1:1,000 in 5% milk; mouse monoclonal anti-BRCA1 (D-9, Santa Cruz), 1:200 in 5% milk; and mouse monoclonal anti-RAD51 (14B4 Novus bio), 1:1,000 in 5% milk. Patient sample blots were reprobed. Reprobed blots were stripped with Restore Plus Stripping Buffer (Thermo Fisher) and reblocked with 5% milk before reprobing. Blots were tested to ensure all that residual detection reagents were removed. Dual Color Precision Plus Protein standard was used as a molecular-weight standard for western blots.
Cell culture. YUNK1 cells were generated in culture from uninvolved cortical renal tissue from a patient undergoing a radical nephrectomy for kidney cancer. This cell line was grown in DMEM with 10% FBS and was capable of ten passages before senescence. YUNK1 was immortalized with a lentiviral vector containing SV40 large T antigen (Addgene plasmid no. 22298). Lentiviral production was performed with HEK293FT (ATCC) cells and plasmids pMDLg/pRRE, pRSV-Rev and pCMV-VSG-G (Addgene plasmid nos. 12251, 12253 and 8454) in a manner similar to previously described methods 1 . YUNK1 cells were maintained in DMEM, 10% FBS and 1% pen/strep. HEK293FT cells (ATCC) were maintained in DMEM, 10% FBS and 1% pen/strep. After lentiviral infections with TRIPZ-shRNA or GIPZ lentiviruses, cells were maintained in DMEM, 10% FBS, 1% pen/strep and 2 μ g/ml puromycin. For doxycycline-inducible shRNAs, expression was induced with 2 μ g/ml doxycycline. Doxycycline-induced knockdown was monitored by western blotting as well as by RFP fluorescence from the internal and doxycyclineinducible reporter on the TRIPZ construct. U2OS DR-GFP cells were as previously described 15 and were maintained in DMEM, 10% FBS and 1% pen/strep. UOK 262 and UOK 268 HLRCC cells were as previously described 7, 8 . They were obtained from W. M. Linehan and were maintained in DMEM, 10% FBS, 1% pen/strep and 1 mM sodium pyruvate. NCCFH1 cells were as previously described 9 shRNA. Doxycycline-inducible shRNA knockdowns were performed with TRIPZ doxycycline-inducible shRNA lentiviruses available from GE Dharmacon. Lentiviral particles were produced with plasmids pMDLg/pRRE, pRSV-Rev and pCMV-VSG-G (Addgene plasmid nos. 12251, 12253 and 8454). The TRIPZ shRNA clones used were as follows: shFH1, GE Dharmacon, V3THS_324846; TRIPZ shFH2, GE Dharmacon, V3THS_324847; TRIPZ shSDHB1, GE Dharmacon, V3THS_346327; TRIPZ shSDHB2, GE Dharmacon, V3THS_347328; and TRIPZ nontargeting control, GE Dharmacon, RHS4743. Pooled populations and single-cell clones were selected with 2 μ g/ml puromycin and maintained in selective medium. Single-cell clones were derived by limiting dilution. shRNA expression was induced with 1 μ g/ml doxycline for 4 d before the start of each assay, and repression of the target proteins was routinely monitored by western blotting. Constitutive shRNA knockdown shRNA lentivirus particles were produced with identical protocols using following the GIPZ lentiviral constructs. shFH1, GE Dharmacon, V2LHS_83495; shFH2, GE Dharmacon, V3LHS_403312; shSDHB1, GE Dharmacon, V3LHS_346327; shSDHB2, GE Dharmacon, V3LHS_346329; and GIPZ nontargeting control, GE Dharmacon, RHS4348. Cells were selected in 2 μ g/ml puromycin and maintained in selective medium, and clones were isolated by limiting dilution in selective medium.
Neutral comet assays. Neutral comet assays were performed as previously described 6 . Patient tumor samples were processed one at a time, diced with a razor blade on ice to dissociate the cells in cold PBS, counted and suspended in low-melt agarose at a concentration of 2,000 cells per assay. After solidification of the agarose, the cells were immediately lysed, and neutral comet assays on cellline samples were performed as previously described 6 . For doxycycline-inducible shRNA knockdown of FH and SDHB, the assays were performed 5 d after induction of shRNA with 2 μ g/ml doxycycline. For plasmid transfection assays, 1 × 10 5 cells per well were seeded in 12-well dishes and allowed to attach overnight. The next day, the cells were transfected with 1 μ g of pCMV-FH (Origene), pCMV-HA-JMJ2A (KDM4A) (Addgene), pCMV-HA-JMJ2B (KDM4B) (Addgene) or pCMV-HA-GASC1 (KDM4C) (Addgene) with 1 μ l of Lipofectamine 3000 and 1 μ l of p3000 reagent. 48 h, later cells were collected on ice, suspended in PBS and then adjusted to a concentration of 2,000 cells per assay in low-melt agarose. For assays following treatment with exogenous metabolites, the metabolites were added 24 h before performing the neutral comet assay. Data are presented as means of three biological replicates ± s.e.m. Replicates reflect independent cultures for in vitro assays. For analysis of patient samples, three replicates were performed on each patient tissue sample. Comet Assay data are presented as mean comet tail moment; comet tail moment was caluclated by multiplying the length of the comet tail by the percentage DNA in the comet tail. γH2AX ELISA. Formalin-fixed, paraffin-embedded samples were collected as 10-μ M slices off the tissue block. Samples were deparaffinized with three washes in 1 ml xylene. Samples were then washed three times in 100% ethanol followed by three times in 85% ethanol and three times in 70% ethanol. Samples were then incubated in extraction buffer (20 mM Tris, pH 8.8, 100 mM DT and 2% SDS) and incubated at 100 °C for 20 min, then at 60 °C for 2 h. Protein extracts were quantified with the DC Protein Assay (Bio-Rad) and then stored at -20 °C. The γ H2AX ELISAs were performed with an γ H2AX Pharmacodynamic Assay Kit per the manufacturers protocol, with an input of 2 μ g protein per replicate. Data are presented as means of three biological replicates ± s.e.m.
Luciferase-based reporter assays for homology-directed repair and nonhomologous end-joining. These assays were as previously described 6 . Briefly, the HR luciferase reporter construct was generated by cloning an inactivating I-SceI recognition site into the BstBI site in the firefly luciferase gene, at a location corresponding to amino acid 56, in the gWIZ.luciferase vector (Genlantis) and cloning a promoterless copy of the firefly luciferase ORF 700 bp downstream in reverse orientation as a donor template for HR. A DSB in the firefly luciferase gene was induced by I-SceI digestion and confirmed by electrophoresis. Linearized plasmid was then transfected into cells to measure HR as a function of luciferase activity (firefly luciferase activity can be restored only by HR, which removes the inactivating I-SceI site). To assay NHEJ, a HindIII-mediated DSB was generated between the promoter and the coding region of the firefly luciferase gene in the pGL3-Control vector (Promega) and confirmed by electrophoresis. After transfection of linearized plasmid, repair of the DSB by NHEJ restored firefly luciferase activity. All reporter assays were performed in 12-well format by seeding of 1 × 10 5 cells per well 24 h before transfection and transfection of 1 μ g of reporter or positive-control vector and 50 ng of Renilla luciferase vector (as a transfection control) per well. For HR, cells were analyzed 48 h after reporter transfection, and for NHEJ, cells were analyzed 24 h after reporter transfection. Luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega) for all samples and normalized to Renilla luciferase signal to control for transfection efficiency, to the positive-control luciferase expression vector (gWIZ.luciferase for HR or pGl3-Control for NHEJ). Data are presented as means of three biological replicates ± s.e.m. U2OS DR-GFP assays. U2OS DR-GFP assays were performed as previously described 6, 15 . siRNAs were transfected to a final concentration of 20 nM, and cells were assayed 96 h after siRNA transfection. Metabolites were added to the cells at the indicated concentrations 24 h before the assays.
Clonogenic survival assay. After 5 d of doxycycline exposure for the shRNA models, cells in culture were irradiated at varying doses of IR. Four hours after irradiation, they were trypsinized, washed, counted and seeded in six-well plates in triplicate at threefold dilutions, ranging from 1,200 to 300 cells per well. For drug treatments, cells were seeded 24 h before addition of the drug. PARP inhibitors were added and remained on the cells for the duration of the assay. Cisplatin treatment lasted 24 h, and MMC and etoposide treatments lasted 1 h. For assays that included treatment with exogenous metabolites, the metabolites were added 24 h before the drug treatment. Plates were incubated for 10-14 d until colonies formed. Colonies were fixed with 2% formaldehyde, then stained with crystal violet and quantified.
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Immunofluorescence and foci assays. The primary antibodies were as follows: mouse anti-γ H2AX (1:400; 05-636; EMD Millipore), rabbit phospho-53BP1 (1:300; 2675; Cell Signaling Technology) and rabbit anti-Rad51 (1:300; PC130-100; EMD Millipore). The secondary antibodies were as follows: anti-mouse AF Plus 488, anti-mouse AF Plus 647, anti-rabbit AF Plus 488 and anti-rabbit AF Plus 647 (1:400; A32723, A32728, A32731 and A32733; Thermo Fisher Scientific). Cells were seeded in chamber slides and subsequently were fixed and permeabilized in 3% PFA, 0.2% Triton-X-100 and 2% sucrose for 20 min and blocked with 10% bovine serum albumin in PBS overnight at 4 °C. Proteins were stained overnight at 4 °C with primary antibodies diluted in blocking solution. After being washed three times with 0.5% Triton X-100 in PBS, samples were incubated with secondary antibodies for 90 min at RT. DNA was stained with DAPI (2.5 µ g/ml; 1816957; Thermo Scientific) for 20 min at RT. After cells were stained and washed three times, chambers were removed from the slides, and the slides were covered with coverslips with Dako Fluorescence Mounting Medium (S3023). Images were analyzed with a Nikon Eclipse Ti fluorescence microscope with a Plan Apo 60× /1.40 oil DIC h objective, a CSU-W1 confocal scanning unit with an iXon Ultra camera (Andor Technology), an MLC 400B laser unit (Agilent Technologies) and NIS Elements 4.30 software (Nikon Corporation). Foci were analyzed with Focinator v2-21 software, as previously described 21 . Analysis of RAD51 foci plus radiation was performed 4 h after 2-Gy IR. Cells with > 20 foci per nucleus were considered RAD51 positive. For γ H2AX, > 15 foci per nucleus were considered foci-positive cells, and for p53BP1 analysis, > 5 foci per nucleus were considered foci-positive cells.
LC-MS/MS. The concentrations of succinate and fumarate in frozen tissue and cell samples were determined with a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, as described below. The calibration curve was prepared in distilled water, with the concentration range of 0.002-10 µ M for succinate and 0.02-100 µ M for fumarate. The intra-and interday precision and accuracy of the quality-control samples met the generally accepted criteria for bioanalytical methods (i.e., < 15%).
Sample preparation. Tissue homogenates were prepared by addition of 100 µ l of distilled water to a weighted tissue sample (~20 mg) followed by homogenization with a Precellys homogenizer (at 6500 r.p.m. twice for 20 s with a 5-s pause). Cell homogenate was prepared by addition of 500 µ l water to the cell pellet (~5 million cells) and subsequent sonication. Into tissue or cell homogenate (original or 20-fold-diluted sample), the stable-isotope-labeled internal standards D 6 succinate and 1,4-13 C 2 , 2,3-D 2 fumarate were added and vortex mixed. Then, 60 µ l was collected, and protein was precipitated by addition of 240 µ l of ice-cold methanol. The supernatant was transferred to a 2-ml tube; 0.1 ml of ice-cold 80% methanol was added to the precipitated pellet, and this was followed by vortex-mixing and centrifugation (at 10,000 r.p.m., 4 °C for 10 min). The supernatants from two extractions were combined and dried down with a CentriVap Refrigerated Centrifugal Concentrator at 10 °C. The residue was reconstituted in 60 µ l distilled water, vortex-mixed and centrifuged, and 5 µ l of the supernatant was injected into the LC-MS/MS system.
LC-MS/MS analysis.
All LC-MS/MS analyses were performed on an AB SCIEX QTRAP 6500 system consisting of an enhanced high-performance hybrid triplequadrupole/linear ion-trap mass spectrometer interfaced with a Shimadzu Nexera ultra-high-performance liquid chromatography system. Chromatographic separation was achieved on a Synergi RP column (2.0 mm × 150 mm, 4 µ m) under a gradient elution consisting of mobile phase A (0.03% formic acid in water) and mobile phase B (0.03% formic acid in acetonitrile), at a flow rate of 0.25 ml/min. Succinate, fumarate and their respective internal standards were monitored under negative electrospray ionization mode at the mass transitions of 117.0 > 73.0, 114.9 > 71.0, 121.0 > 76.9 and 119.0 > 74.0, respectively. Analyst 1.6 software was used for system control and data acquisition, and MultiQuant 3.0 software was used for data processing and quantification.
In vivo efficacy studies. HEK293FT xenografts. Female athymic nu/nu mice (Hsd:Athymic Nude-Foxn1nu, Envigo) were used for all in vivo xenograft studies. All animal experiments were performed in accordance with the relevant guidelines and regulations. All studies were approved by the Yale University Institutional Animal Care and Use Committee. Mice were quarantined for at least 1 week before experimental manipulation. Tumors were formed with shRNA-expressing versions of the tumorigenic human embryonic kidney cell-derived line HEK293FT. HEK293FT is a subline of HEK293 cells that has been transformed by expression of SV40 large T antigen. HEK293FT cells expressing TRIPZ-shSDHB, shFH or shCtrl (nontargeting control) were implanted subcutaneously (5 × 10 6 cells in 0.1 cc PBS) in the right flank in nude mice. Two efficacy studies were conducted.
In one study, mice were randomized into treated and nontreated groups (ten mice per group) at day 3, with treatment initiation 4 d after implantation. In a second independent in vivo efficacy study, ten mice per group were injected as above, and treatment was started only after the tumor volumes reached 95-150 mm 3 . For both studies, mice were visually observed daily, and tumors were measured three times per week with calipers to determine tumor volume with the following formula: volume = length × width × width × 0.532. Mice were fed with a grain-based rodent diet containing doxycycline at 200 mg/kg (Bioserv, S3888). BMN-673 was solubilized in DMSO and diluted with PBS containing 10% dimethylacetamide (Sigma-Aldrich) and 6% Solutol (Sigma). BMN-673 (0.5 mg/kg, 0.2 cc) or vehicle (0.2 cc) was administered by oral gavage once daily for the duration of the experiment. Mean (geometric) tumor volume (mm 3 ) was plotted over time to monitor tumor growth.
UOK 262 xenografts. Female athymic nu/nu mice (Hsd:Athymic Nude-Foxn1nu, Envigo) were used for all in vivo xenograft studies. The authors confirm that all animal experiments were performed in accordance with relevant guidelines and regulations. All studies were approved by the Yale University Institutional Animal Care and Use Committee. Mice were quarantined for at least 1 week before experimental manipulation. UOK 262 cells were implanted subcutaneously with 5 × 10 6 cells in 0.1 cc PBS mixed with 0.1 cc of Corning Matrigel matrix (354234) per animal. Mice were randomized at day 3 into two groups (n = 10 per group). Olaparib (Selleckchem) was solubilized in DMSO and diluted with 10% (wt/vol) 2-hydroxy-propyl-beta-cyclodextrin (Sigma) to obtain the desired concentration and delivered via intraperitoneal injection (50 mg/kg) once daily, 5 d per week. In a second UOK 262 in vivo efficacy study, mice were randomized into treatment and control groups (n = 6 per group) after the tumor volume reached 250 mm 3 . The control group received the vehicle, and the other group received BMN-673 (0.5 mg/kg, 0.2 cc) through gavage administered daily.
LC-MS analysis of intratumoral BMN-673.
TRIPZ-shSDHB or shCtrl (nontargeting control) human embryonic kidney cells (5 × 10 6 cells in 0.1 cc PBS) were injected subcutaneously in both flanks. Tumors developed in mice on a rodent diet including doxycycline, as in the in vivo efficacy studies. After the tumors had reached 80 mm 3 , mice were gavaged with BMN-673 at 1 or 10 mg/kg or vehicle. Tumors were collected 24 h later and frozen at -80 °C. The concentrations of BMN-673 in tumor samples were determined with LC-MS/MS. In brief, an aliquot (30 µ l) of tumor homogenate was protein-precipitated with three volumes of methanol, and 5 µ l of supernatant was injected into the LC-MS/MS system. LC-MS/MS analyses were performed on a Waters LC-MS/MS system consisting of a Waters AQUITY UPLC system coupled with a TQ-XS triple-quadrupole mass spectrometer. Chromatographic separation was achieved on an XBridge C18 column (2.1 × 50 mm, 3.5 µ m) with a gradient elution consisting of acetonitrile and 0.1% formic acid in water, at a flow rate of 0.4 ml/min. BMN673 was monitored with positive electrospray ionization mode at the most sensitive and specific mass transition, m/z 381.0 > 228.8. The linear calibration curve was established at a BMN673 concentration range of 5-5,000 nM in mouse serum. The precision and accuracy of quality-control samples met generally acceptable criteria for bioanalytical methods.
Poly(ADP)-ribose ELISA. Poly(ADP)-ribose ELISA was performed per the manufacturer's protocol with a PARP in vivo Pharmacodynamic Assay II Kit (Trevigen). 2 µ g of protein input was used per replicate, and luminescence readings were converted to pg PAR/µ g protein with a standard curve.
Statistics and reproducibility.
Data are shown as means ± s.e.m. and were compared with two-sided t tests or ANOVA with repeated measures when appropriate. Statistical analyses were carried out in GraphPad Prism and Stata software. Replicates were defined as individual cultures for all in vitro assays, and statistical analysis was performed on measurements from independent cultures. For in vivo assays, replicates were defined as individual mice bearing a xenograft tumor. Samples sizes were determined based off biological triplicates for in vitro assays. For in vivo assays number of sample sizes were determined a priori.
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful and data represent the mean of 3 biological replicates. For in vitro assays each replicate was defined as an independent culture of cells. In the case of DOX inducible shRNA the knockdown was independently induced in different cultures. For animal experiments n refers to the number of animals implanted with a xenograft tumor.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
In vitro assays were not conducted in a random or blinded manner. Xenograft tumors were randomly assigned into treatment or control groups 3 days after injection and measured in a blinded fashion.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Focinator V 2.0 was used to analyze Immunfluorescence images. Statistical Analysis was done in PRISM 7 or Stata. Figures were compiled using Adobe Illustrator.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There are no limitations 10. Eukaryotic cell lines a. State the source of each eukaryotic cell line used. ATCC for cell lines We derived the YUNK1 cells from a patient tumor as described in the manuscript UOK262 and UOK268 obtained from W.M. Linehan . NCCFH1 cells were obtained from B.T Teh.
b. Describe the method of cell line authentication used. STR analysis of ATCC cell lines c. Report whether the cell lines were tested for mycoplasma contamination.
Yes we tested for mycoplasma, and they were negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used
